← Trials/Trial dossier/NCT02931136

UnknownPhase 4

Early Diagnosis and Early Treatment of Alzheimer's Disease Based on Senile Plaque Imaging

Lead sponsor

Shanghai Mental Health Center

Asset

Huperzine A

Listed sites

Recruiting sites

Enrollment

300

estimated

Study population

Alzheimer’s disease, MCI / preclinical Alzheimer’s

Key I/E criterion

•Age 55-85

Primary endpoint

•Average annual conversion rate

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT02931136

Org study IDShanghai Mental Health Center

Timeline

Milestones

Study first posted2016-10-12estimated

Last update posted2019-04-16actual

Study start2019-11estimated (month precision)

Primary completion2024-12estimated (month precision)

Study completion2025-12estimated (month precision)

Assets

Drug assets

Huperzine A

Study populations

Who this study enrolls

Alzheimer’s diseaseMCI / preclinical Alzheimer’s

Eligibility

Who can enroll

Minimum age55 Years

Maximum age85 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•memory complaint, preferably corroborated by a spouse or relative.

•objective memory impairment.

•normal general cognitive function.

•intact activities of daily living.

•absence of dementia.

•the positive of brain senile plaque

Exclusion criteria

•more than two lacuna ischemia (of diameter < 1 cm) as revealed by MRI fluid-attenuated inversion recovery (FLAIR) sequence.

•other type of dementia except AD

Endpoints (1)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Other (unclassified)

1 endpoint

Primary/protocol endpoint/low confidence

The average annual conversion rate in patients of MCI due to AD convert to the AD.

Time frame:52 weeks

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 21, 2026

Endpoint classificationDelfa ADRD endpoint taxonomy

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.